RE:Much more than a NibbleGoldenInvestor wrote: Sure there are is the promise of loan repayment & interest compounded !
But there is also 1,500,000 warrants AND
2 POTENTIAL PRV's!
with the benefits of potential company ownership, there is the potential of significant upside in the drug Dev side for Knight & the possible sale of 2 PRV's if they choose to go that route!!
anyone know the VALUE of the sale of ONE of those? with warrants & future shares.., possibilities
GENIUS
Yes - but all those benefits reside with Appili and Goodman (along with the risk) as Samira/GUD is likely focusing on licensing developed drugs. Goodman is willing to take the risk. I can only guess that if he ever gets rights to the drugs in those locations, GUD would likely get first opportunity to purchase the rights for Canada, Israel and LATAM from him.
Actually ... as of this morning, Appili has added a third drug with PRV potential. Licensing ATI-1801 from the U.S. Department of Defense. Looks like it's a safer version of the product for which GUD got their PRV. I don't think the market size is all that big for this drug - but safer ... and needed.
GUD sold their PRV for $140M CAD but the value likely coincides with timing of blockbuster drugs in a company's pipeline and the competitive nature with other drugs also coming to market at that time. Value can swing but we know what Goodman will do - he will recommend they hold the PRV indefinately until the right opportunity comes along. If a small pharma can't wait for the optimal time, Goodman might make an offer for it and he'll hold for the right time to sell.